Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

Phase 1/2 Completed 49 enrolled Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab Northwestern Memorial Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide and vinorelbine in treating patients who have recurrent brain metastases.

Timeline

Start: 2001-07
Primary completion: 2008-04
Completion: 2008-04

Publications

Results Iwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT, Abrey LE. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2008 Mar;87(1):85-90. doi: 10.1007/s11060-007-9491-3. Epub 2007 Nov 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Temozolomide	Small molecule	150 mg/m2	Oral
Subject	Vinorelbine	Small molecule	25 mg/m2	Intravenous
Subject	Vinorelbine	Small molecule	30 mg/m2	Intravenous

Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

Summary

Timeline

Publications

Drugs

Indications